🧬 Calling all 2026 iGEM teams! We are excited to support this year's @iGEM Competition by providing up to 𝟮𝟬 𝗸𝗯 𝗼𝗳 𝘀𝘆𝗻𝘁𝗵𝗲𝘁𝗶𝗰 𝗰𝗹𝗼𝗻𝗮𝗹 𝗗𝗡𝗔 𝘁𝗼 𝟮𝟬 𝘀𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝘁𝗲𝗮𝗺𝘀.
Applications are open through June 30.
👉Apply: https://t.co/vM8PRMwv2C
📣 WEBINAR ALERT: Join us to explore how gene design choices can impact antibody expression outcomes.
🗓️Thursday, June 11
⏲️ 8am PT 🔹11 am ET 🔹3pm GMT
Featuring Justin Byers and Daniel Lin-Arlow, this session will also include a live Q&A.
👉 https://t.co/xZL43H3HO4
We’re partnering with @AnsaBio to provide customers with access to long, #complexDNA, ranging from 100 bp to 50 kb! Take a look at how this collaboration has delivered value to Manos Papadakis, senior research scientist, strain development, @dsmfirmenich. 👇
Learn more here: https://t.co/UO0Hxh4R5q
Codon optimization is one of the most widely used (and misunderstood) tools in synthetic biology. And in many cases, the biggest limitation isn’t biology... it’s manufacturability.
We dig into the issue on our blog.
🔗 https://t.co/PoWimtCz2A
From synthetic biologist to startup founder to leading the scientific vision of a company pushing the boundaries of what’s possible in DNA synthesis.
@TheScientistLLC spotlights the journey, mindset & curiosity of our CSO & Co-Founder, Daniel Lin-Arlow.
https://t.co/d6NHq52Axz
🧬 How far can your DNA take you?
For most teams, the answer is still constrained by what can actually be built. At Ansa, we’ve removed that limitation so you can design to the needs of biology, not the constraints of your typical DNA provider.
👉 https://t.co/DkaPRqCz4k
Jason T. Gammack said @AnsaBio shipped 47 megabases of DNA, about 26,000 genes, with a 97.3% fulfillment rate as it expands clonal DNA up to 50 kb through @idtdna. #SynBioBeta#Biotech
@johncumbers@Jason_Gammack@AnsaBio@SynBioBeta 50kb perfect constructs change what I dare to design. When synthesis becomes reliable infrastructure rather than a bottleneck, I stop working around supplier limitations and start building the biology I actually want.
"The constraints we've been taught to accept are not laws of nature—they're artifacts of legacy manufacturing.”
Ansa CEO @Jason_Gammack gives his perspective ahead of #SynBioBeta.
👉 https://t.co/hE3HkIstCJ
We can read DNA.
We can design DNA.
But building it?
Still one of the biggest bottlenecks in biology.
To mark #DNADay, we're sharing a chat with Ansa CEO @Jason_Gammack about where the field is going: https://t.co/6Itx3ejcQR
As we reflect on #sustainability in science this #EarthDay, there’s an uncomfortable question worth asking: Why does the foundation of synthetic biology still rely on processes that generate so much waste?
We believe there's a better way.
Learn more: https://t.co/2ZR6iQ1PGm
AI design algorithms are generating more ambitious DNA constructs than legacy synthesis can handle.
High GC content, repetitive sequences, long constructs that require assembly and cloning work that takes weeks in the lab.
That's the bottleneck.
@AnsaBio is attacking it with enzymatic synthesis: no harsh chemicals, no damage to the growing molecule, direct synthesis of sequences up to 1,005 bases (a world record) assembled into constructs up to 50 kb, delivered in under four weeks.
@Jason_Gammack presents at @SynBioBeta 2026 with real-world data on where enzymatic synthesis outperforms legacy methods and what it actually changes about the build vs. buy decision for complex DNA.
SynBioBeta 2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK
After 20+ years in DNA synthesis, Ansa’s new COO Matthias Arenskötter shares why the field needs a new approach, and how long, reliable DNA unlocks real design freedom.
📖 https://t.co/0N0TTX4ENU
We’re excited to welcome Matthias Arenskötter as Ansa’s new COO. With 20+ years in DNA synthesis and deep expertise in scaling advanced manufacturing, Matthias will lead global ops as we meet rising demand for long, complex DNA.
🔗https://t.co/Shc6KuG2uN
#Biosecurity isn’t a ‘nice to have’ in DNA synthesis. It’s a core responsibility.
We screen & verify every DNA order before manufacturing begins, w/ automated sequence checks, expert review & strong data security to protect sensitive designs.
👉 https://t.co/FCGHE1NazU
The biggest limitation in DNA synthesis isn’t cost. It’s:
• Sequence rejection
• Unpredictable timelines
Accessing complex DNA is only half the problem.
Getting it when you expect it is what keeps science moving.
📑 Read the Tech Note here: https://t.co/ePaSdY4fdH
Behind every shipment is a team committed to getting it right.
This is the final step before orders ship under the Ansa On-Time Guarantee—helping scientists receive sequence-verified clonal DNA reliably and on schedule.
📣 Our team is excited to share that our synthetic DNA contributed to a new study in @Nature led by @arcinstitute introducing the Evo 2 genomic foundation model.
📑 Read the paper: https://t.co/A2y9Sz3jEI
Evo 2, our fully open-source biological foundation model trained on trillions of DNA tokens spanning the entire tree of life, is out in @Nature today
We & the scientific community have done a lot with this @arcinstitute@nvidia model in the last year! 🧵👇
@BrianHie@pdhsu@Nature This would not have been possible without @AnsaBio providing the synthetic DNA. Their up to 50kb clonal DNA without any sequence restrictions is an absolute game changer!